LSI Segment Divestment

CORE EBITDA Margin Drivers Productivity measures mitigate ramp-up costs CORE EBITDA margin FY20191 31.7% Growth project ramp-up Cost control and operational exelence Business mix CORE EBITDA margin FY2020 31.2% 1 Restated to reflect the classification of Specialty Ingredients as discontinued operations Upfront hiring for growth projects in launch/ramp-up phase Reduced admin costs through productivity measures and COVID-19 tailwinds (e.g., travel) Continued focus on operational excellence in manufacturing operations - Investments in high-growth businesses like Cell & Gene Therapy and Personalized Medicine CORE definition: See appendix 14

View entire presentation